Published in Gynecol Oncol on October 01, 2004
Maximal cytoreductive effort in epithelial ovarian cancer surgery. J Gynecol Oncol (2010) 1.11
Safety and efficacy of video laparoscopic surgical debulking of recurrent ovarian, fallopian tube, and primary peritoneal cancers. JSLS (2013) 0.85
Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter? Br J Cancer (2013) 0.82
Therapeutic Efficacy of Alpha-RIT Using a (213)Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal Carcinomatosis. Front Med (Lausanne) (2015) 0.78
Tertiary cytoreduction in the setting of recurrent ovarian cancer (Review). Oncol Lett (2013) 0.75
Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy to Treat Advanced/Recurrent Epithelial Ovarian Cancer: Results from a Retrospective Study on Prospectively Established Database. Transl Oncol (2016) 0.75
Survival Impact of Secondary Cytoreductive Surgery for Recurrent Ovarian Cancer in an Asian Population. Oman Med J (2015) 0.75
Feasibility of laparoscopic cytoreduction in patients with localized recurrent epithelial ovarian cancer. J Gynecol Oncol (2016) 0.75
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2002) 7.84
Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res (2005) 4.14
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol (2008) 3.54
Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol (2009) 2.45
Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol (2008) 2.25
Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol (2006) 2.23
The rate of port-site metastases after 2251 laparoscopic procedures in women with underlying malignant disease. Gynecol Oncol (2008) 2.14
Incidence of venous thromboembolism after minimally invasive surgery in patients with newly diagnosed endometrial cancer. Obstet Gynecol (2012) 2.09
Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer (2006) 2.03
Clinicopathologic features of rhabdomyosarcoma of gynecologic origin in adults. Am J Surg Pathol (2007) 1.79
Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. Int J Radiat Oncol Biol Phys (2005) 1.77
Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol (2003) 1.74
Fertility-sparing radical abdominal trachelectomy for cervical carcinoma: technique and review of the literature. Gynecol Oncol (2006) 1.73
Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging. Int J Gynecol Cancer (2013) 1.71
Treatment effects, disease recurrence, and survival in obese women with early endometrial carcinoma : a Gynecologic Oncology Group study. Cancer (2006) 1.71
Subcutaneous tumor implantation after laparoscopic procedures in women with malignant disease. Obstet Gynecol (2004) 1.69
The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol (2006) 1.64
Molecular profiling of endometrial cancers from African-American and Caucasian women. Gynecol Oncol (2005) 1.62
The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol (2010) 1.61
Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol (2004) 1.60
The revised 2009 FIGO staging system for endometrial cancer: should the 1988 FIGO stages IA and IB be altered? Int J Gynecol Cancer (2011) 1.60
Twelve-year experience in the management of endometrial cancer: a change in surgical and postoperative radiation approaches. Gynecol Oncol (2007) 1.56
Pelvic exenteration with curative intent for recurrent uterine malignancies. Gynecol Oncol (2011) 1.55
Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol (2007) 1.54
The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecol Oncol (2012) 1.52
The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecol Oncol (2006) 1.51
Impact of operative start time on surgical outcomes in patients undergoing primary cytoreduction for advanced ovarian cancer. Gynecol Oncol (2012) 1.47
En bloc resection of diaphragm with lung for recurrent ovarian cancer: a case report. Gynecol Oncol (2006) 1.44
Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature. Gynecol Oncol (2007) 1.44
Pilot study prospectively evaluating the use of the measurement of preoperative sonographic endometrial thickness in postmenopausal patients with endometrial cancer. Menopause (2005) 1.43
Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol (2003) 1.43
Ventral hernia following primary laparotomy for ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol (2010) 1.42
Ureteroileocecal appendicostomy based urinary reservoir in irradiated and nonirradiated patients. J Urol (2009) 1.38
The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol (2010) 1.37
Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183. J Clin Oncol (2005) 1.35
Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma? Gynecol Oncol (2009) 1.35
The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes. Gynecol Oncol (2009) 1.33
Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer (2011) 1.32
Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol Oncol (2005) 1.32
A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol (2007) 1.31
The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol (2007) 1.28
CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol (2006) 1.28
Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems. J Clin Oncol (2009) 1.27
Genetic analysis of the early natural history of epithelial ovarian carcinoma. PLoS One (2010) 1.25
Surgical management of recurrent ovarian cancer. Semin Oncol (2009) 1.24
Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol Oncol (2010) 1.23
Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer? Int J Radiat Oncol Biol Phys (2002) 1.21
Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol (2006) 1.20
Surgical and pathologic outcomes of fertility-sparing radical abdominal trachelectomy for FIGO stage IB1 cervical cancer. Gynecol Oncol (2008) 1.20
A microRNA survival signature (MiSS) for advanced ovarian cancer. Gynecol Oncol (2011) 1.18
Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. J Clin Oncol (2006) 1.18
A fertility-sparing alternative to radical hysterectomy: how many patients may be eligible? Gynecol Oncol (2004) 1.17
Oncologic outcome of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma. Gynecol Oncol (2008) 1.16
A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. Gynecol Oncol (2009) 1.14
Clinicopathologic analysis of early-stage sporadic ovarian carcinoma. Am J Surg Pathol (2004) 1.13
Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer (2004) 1.12
Cystoscopic temporary ureteral catheterization during radical vaginal and abdominal trachelectomy. Gynecol Oncol (2006) 1.12
Establishing a sentinel lymph node mapping algorithm for the treatment of early cervical cancer. Gynecol Oncol (2011) 1.11
Clinicopathologic features of bone metastases and outcomes in patients with primary endometrial cancer. Gynecol Oncol (2010) 1.11
Maximal cytoreductive effort in epithelial ovarian cancer surgery. J Gynecol Oncol (2010) 1.11
Radical vaginal versus abdominal trachelectomy for stage IB1 cervical cancer: a comparison of surgical and pathologic outcomes. Gynecol Oncol (2008) 1.10
Retroperitoneal nodal metastasis in primary and recurrent granulosa cell tumors of the ovary. Gynecol Oncol (2006) 1.10
Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. Gynecol Oncol (2003) 1.09
Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma? Am J Obstet Gynecol (2008) 1.09
Radical trachelectomy for cervical cancer: postoperative physical and emotional adjustment concerns. Gynecol Oncol (2008) 1.08
Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma. Gynecol Oncol (2007) 1.07
Total laparoscopic radical hysterectomy with pelvic lymphadenectomy using the argon-beam coagulator: pilot data and comparison to laparotomy. Gynecol Oncol (2003) 1.07
The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol (2007) 1.07
The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers. Am J Obstet Gynecol (2005) 1.06